Annual Cash & Cash Equivalents
$331.15 M
+$52.10 M+18.67%
December 31, 2023
Summary
- As of February 8, 2025, KROS annual cash & cash equivalents is $331.15 million, with the most recent change of +$52.10 million (+18.67%) on December 31, 2023.
- During the last 3 years, KROS annual cash & cash equivalents has risen by +$65.27 million (+24.55%).
- KROS annual cash & cash equivalents is now at all-time high.
Performance
KROS Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$530.68 M
+$124.82 M+30.75%
September 30, 2024
Summary
- As of February 8, 2025, KROS quarterly cash and cash equivalents is $530.68 million, with the most recent change of +$124.82 million (+30.75%) on September 30, 2024.
- Over the past year, KROS quarterly cash and cash equivalents has increased by +$199.54 million (+60.26%).
- KROS quarterly cash and cash equivalents is now at all-time high.
Performance
KROS Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
KROS Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +18.7% | +60.3% |
| 3 y3 years | +24.6% | +139.8% |
| 5 y5 years | +1323.7% | - |
KROS Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +44.0% | at high | +146.1% |
| 5 y | 5-year | at high | +4617.2% | at high | +7459.6% |
| alltime | all time | at high | +4617.2% | at high | +7459.6% |
Keros Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $530.68 M(+30.8%) |
| Jun 2024 | - | $405.86 M(-8.3%) |
| Mar 2024 | - | $442.44 M(+33.6%) |
| Dec 2023 | $331.15 M(+18.7%) | $331.15 M(+15.0%) |
| Sep 2023 | - | $287.89 M(-10.6%) |
| Jun 2023 | - | $322.03 M(-8.4%) |
| Mar 2023 | - | $351.43 M(+25.9%) |
| Dec 2022 | $279.05 M | $279.05 M(+16.5%) |
| Sep 2022 | - | $239.43 M(+11.0%) |
| Jun 2022 | - | $215.62 M(-5.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $228.59 M(-0.6%) |
| Dec 2021 | $230.04 M(-13.5%) | $230.04 M(+3.9%) |
| Sep 2021 | - | $221.35 M(-6.6%) |
| Jun 2021 | - | $237.11 M(-7.1%) |
| Mar 2021 | - | $255.20 M(-4.0%) |
| Dec 2020 | $265.88 M(+3687.4%) | $265.88 M(+98.7%) |
| Sep 2020 | - | $133.81 M(-7.5%) |
| Jun 2020 | - | $144.69 M(+165.4%) |
| Mar 2020 | - | $54.52 M(+676.6%) |
| Dec 2019 | $7.02 M(-69.8%) | $7.02 M |
| Dec 2018 | $23.26 M | - |
FAQ
- What is Keros Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Keros Therapeutics?
- What is Keros Therapeutics annual cash & cash equivalents year-on-year change?
- What is Keros Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Keros Therapeutics?
- What is Keros Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Keros Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of KROS is $331.15 M
What is the all time high annual cash & cash equivalents for Keros Therapeutics?
Keros Therapeutics all-time high annual cash & cash equivalents is $331.15 M
What is Keros Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, KROS annual cash & cash equivalents has changed by +$52.10 M (+18.67%)
What is Keros Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of KROS is $530.68 M
What is the all time high quarterly cash and cash equivalents for Keros Therapeutics?
Keros Therapeutics all-time high quarterly cash and cash equivalents is $530.68 M
What is Keros Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, KROS quarterly cash and cash equivalents has changed by +$199.54 M (+60.26%)